NEW YORK (GenomeWeb News) – Through eight months ending May 31, 2012, Dako posted $242 million in revenues, Agilent Technologies disclosed in a regulatory filing after the close of the market on Wednesday, which also disclosed Dako's earnings for full-year 2011 and for the six months ended March 31.
Agilent completed its $2.2 billion purchase of the Danish cancer diagnostics company in June.
In a document filed with the US Securities and Exchange Commission on Wednesday, Agilent said that Dako had a net loss of $61 million on a GAAP basis for the eight months ended May 31. R&D spending during the period totaled $37 million and SG&A costs were $100 million.
During the six months ended March 31, Dako posted revenues of $183 million and a net loss of $23 million. It spent $24 million on R&D and $76 million on SG&A. In full-year 2011, the firm had a loss of $43 million on revenues of $361 million. R&D spending was $51 million for FY 2011, while SG&A spending was $155 million.